TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9368804
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g added triglycerides
Study: 9368804
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g added triglycerides
Study: 9368804
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g added triglycerides
Study: 9368804
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g added triglycerides
Study: 9368804
Drug: All triglyceride
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All triglyceride amounts (0, 15, 30, 40 g)
Study: 9368804
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g or more added triglycerides
Study: 9368804
Drug: 0 to
Normalized name: U40 Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 to 40 g added triglycerides
Study: 7692173
Drug: Isradipine regular
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine regular formulation (RF) 2.5 mg twice daily
Study: 7692173
Drug: Isradipine modified
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine modified release (MR) 5 mg once daily
Study: 3955199
Drug: Intravenous prenalterol
Normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous prenalterol
Study: 3955199
Drug: Sustained-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release formulation of prenalterol
Study: 31724351
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy regimen combined with symptomatic treatment (antiemetic, acid-suppressive, liver-protecting drugs).
Study: 28478653
Drug: Venlafaxine-lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine-lithium treatment strategy
Study: 28478653
Drug: Imipramine-lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine-lithium treatment strategy
Study: 25415373
Drug: Fixed fluence
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed fluence (FF) treatment
Study: 25415373
Drug: Judged fluence
Normalized name: Florence fennel
DrugBank: Fennel (DB15615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Judged fluence (JF) treatment
Study: 21654918
Drug: In-home training
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-home training for fathers, skills taught: following the child's lead, imitation with animation, commenting on the child, expectant waiting, duration: 12 weeks, frequency: twice a week
Study: 17042843
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (30 mg x kg(‐1) before induction, 10 mg x kg(‐1) continuously intra‐operatively)
Study: 12895688
Drug: Panax ginseng
Normalized name: Panax Ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panax ginseng (200 mg G115)
Study: 12895688
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (360 mg GK501)
Study: 1281041
Drug: L-TAE +
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-TAE + ADR
Study: 1281041
Drug: L-TAE
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-TAE
Study: 30273343
Drug: Community-wide biannual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-wide biannual treatment with mass drug administration (MDA)
Study: 30273343
Drug: Annual treatment
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual treatment of children alone with MDA
Study: 27052303
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maintaining daily routines)
Study: 17878468
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of optimal bronchodilator therapy and/or supplemental oxygen therapy with exercise training
Study: 16344836
Drug: MAS XR
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAS XR 30 mg
Study: 16344836
Drug: MAS XR
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAS XR 20 mg
Study: 16344836
Drug: MAS XR
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAS XR 40 mg
Study: 16344836
Drug: MAS XR
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAS XR 60 mg
Study: 12117301
Drug: Hyperhydration induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperhydration induced by ingestion of glycerol (1.1 g/kg body mass) and fluid (21.4 mL/kg body mass)
Study: 11697710
Drug: Mean platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean platelet count before therapy
Study: 9597244
Drug: Four-drug regimen
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug regimen (standard treatment)
Study: 9597244
Drug: Five-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-drug regimen (four drugs plus levofloxacin)
Study: 9597244
Drug: 9 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 9 months of intermittent therapy with isoniazid and rifampin
Study: 9597244
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of intermittent therapy with isoniazid and rifampin
Study: 3108009
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin (Nitroderm‐TTS)
Study: 29440149
Drug: Multimodal cachexia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal cachexia intervention (MENAC trial) including non-steroidal anti-inflammatory drugs, eicosapentaenoic acid, physical exercise program (resistance and aerobic training), dietary counselling, and oral nutritional supplements.
Study: 26170027
Drug: RTA 408
Normalized name: RTA 744
DrugBank: RTA 744 (DB05920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTA 408 Lotion (0.5%, 1%, and 3%) applied twice daily for 14 days
Study: 26170027
Drug: RTA 408
Normalized name: RTA 744
DrugBank: RTA 744 (DB05920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTA 408 Lotion (3%) applied twice daily to a 100-cm² site for 14 days
Study: 26170027
Drug: RTA 408
Normalized name: RTA 744
DrugBank: RTA 744 (DB05920)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTA 408 Lotion (3%) applied twice daily to a 500-cm² site for 28 days
Study: 26170027
Drug: Lotion vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion vehicle applied as control
Study: 23682979
Drug: Immediate antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antibiotic treatment
Study: 23682979
Drug: Delayed antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antibiotic prescribing (DAP) with structured advice to use a course of antibiotics if symptoms worsen or do not improve (prescription given to patient)
Study: 23682979
Drug: Delayed antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antibiotic prescribing (DAP) with structured advice to use a course of antibiotics if symptoms worsen or do not improve (prescription left at the reception of the primary care centre 3 days after the first medical visit)
Study: 21845445
Drug: FRG-E (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: FRG-E (500 μg mouse(‐1))
Study: 12733686
Drug: Lowering intraocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowering intraocular pressure (IOP) through various treatments, specific interventions not detailed, duration not specified.
Study: 1733754
Drug: Valproate therapy
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate therapy (VPA)
Study: 29996802
Drug: Lyophilised vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilised vaccines (BCG, Measles, Yellow Fever)
Study: 29996802
Drug: Multi-dose/single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-dose/single dose vials of liquid vaccines
Study: 27514506
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil (80 mg) and chlorthalidone (25 mg) in fasted condition
Study: 27514506
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil (80 mg) and chlorthalidone (25 mg) 30 minutes after a high‐fat meal
Study: 27514506
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of azilsartan medoxomil and chlorthalidone in fasted condition
Study: 27514506
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of azilsartan medoxomil and chlorthalidone 30 minutes after a high‐fat meal
Study: 24747488
Drug: Home-based Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based Behavioral Activation for Depression (BATD) treatment delivered via web-based video technology
Study: 24747488
Drug: In-office Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office Behavioral Activation for Depression (BATD) treatment
Study: 23285070
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg L-dopa (Madopar)
Study: 20469975
Drug: Amlodipine/valsartan 5/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan 5/80 mg
Study: 20469975
Drug: Amlodipine/valsartan 5/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan 5/80 mg (subgroup n = 82)
Study: 10221486
Drug: Thymoglobulin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin (1.5 mg/kg intravenously)
Study: 10221486
Drug: Atgam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atgam (15 mg/kg intravenously)
Study: 8590509
Drug: 13.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13.5 mg hyperbaric bupivacaine 0.75% + 25 micrograms fentanyl intrathecal (Group II)
Study: 8590509
Drug: 13.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13.5 mg hyperbaric bupivacaine 0.75% + 0.5 ml CSF (Group I)
Study: 108663
Drug: 10% dextrose-amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% dextrose-amino acid solution
Study: 108663
Drug: 10% dextrose-amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% dextrose-amino acid with intravenous fat emulsion
Study: 21623968
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) - 200 μg beclomethasone extra-fine daily for 8 weeks
Study: 19218828
Drug: Single-family therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-family therapy (n = 25)
Study: 19218828
Drug: Multi-family group
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-family group therapy (n = 35)
Study: 19218828
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n = 23)
Study: 11672450
Drug: Lisinopril (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (5-20 mg daily)
Study: 9338727
Drug: Bacille Calmette-Guérin
Normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacille Calmette-Guérin (BCG) 150 mg
Study: 11552904
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg o.m.
Study: 3322922
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg b.i.d.
Study: 23507375
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg orally, administered 4 hours before a match)
Study: 23507375
Drug: Placebo (cellulose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose, administered 4 hours before a match)
Study: 20008243
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with lenalidomide, bortezomib, and dexamethasone
Study: 20008243
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with a single autologous stem cell transplant
Study: 15108985
Drug: Intrathecal hyperbaric
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal hyperbaric bupivacaine (6, 7, 8, 9, 10, 11, or 12 mg) with 10 microg intrathecal fentanyl and 200 microg intrathecal morphine
Study: 11268890
Drug: Long-term oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oxygen therapy (LTO)
Study: 11268890
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (bilateral reduction of lung volume)
Study: 11268890
Drug: Nutritional therapy
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional therapy (special diets)
Study: 11268890
Drug: Psycho-social interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psycho-social interventions (e.g. psychotherapy, training and education)
Study: 9847435
Drug: Racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol 1.25 mg
Study: 25692656
Drug: Freeze dried
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze dried live attenuated Oka strain Varicella Vaccine (VR 795 Oka strain)
Study: 25692656
Drug: Freeze dried
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze dried live attenuated Oka strain Varicella Vaccine (VR 795 Oka strain) and Varilrix (Oka-RIT strain)
Study: 18509557
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (anterior‐posterior joint mobilization over the talus) plus standard physiotherapy programme
Study: 18509557
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy plus standard physiotherapy programme
Study: 7751524
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with atropine
Study: 2717665
Drug: 5-HT agonist
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT agonist (fluoxetine)
Study: 2717665
Drug: 5-HT antagonist
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT antagonist (ritanserin)
Study: 142468
Drug: Isosorbide (osmotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide (osmotic anti-glaucoma medication)
Study: 31438412
Drug: Mobile application
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile application for medication management
Study: 22577108
Drug: Cinacalcet (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (30 mg daily, titrated until calcium normalization)
Study: 19307987
Drug: Medication-only condition
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-only condition
Study: 19485586
Drug: Combined medication
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined medication plus cognitive-behavioral therapy (CBT) condition
Study: 17543129
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (2.5 mgr)
Study: 9821232
Drug: Ramipril 2.5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 2.5‐10 mg/day
Study: 7965279
Drug: Captopril 100
Normalized name: captopril 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 100 mg twice a day
Study: 8121291
Drug: Mepacrine hydrochloride
Normalized name: Mepacrine hydrochloride
DrugBank: Quinacrine (DB01103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepacrine hydrochloride 100 mg three times daily for 7 days
Study: 23383047
Drug: antibiotic use
Normalized name: Antibiotics for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic use
Study: 20574663
Drug: Palonosetron (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (0.25 mg intravenously) and dexamethasone (8 mg intravenously) on day 1
Study: 20574663
Drug: Palonosetron (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (0.25 mg intravenously) and dexamethasone (8 mg intravenously) on day 1 followed by dexamethasone 8 mg orally on days 2 and 3
Study: 19522441
Drug: New antiepileptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antiepileptic drugs (AED) with accurate pathogenic targets
Study: 17140540
Drug: Dental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental treatment (full mouth rehabilitation under general anaesthesia)
Study: 10705631
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of octreotide‐acetate subcutaneously one hour prior to ERCP
Study: 10705631
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of octreotide‐acetate
Study: 7560226
Drug: Systemic Augmentin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic Augmentin therapy (500 mg 1 h prior to surgery, 500 mg TID for 8 days)
Study: 7560226
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no systemic antimicrobial therapy)
Study: 1697419
Drug: Fluvoxamine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (150 mg)
Study: 1697419
Drug: Ritanserin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (20 mg)
Study: 30999929
Drug: Namilumab 20
Normalized name: Namilumab
DrugBank: Namilumab (DB13037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Namilumab 20 mg
Study: 30999929
Drug: Namilumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Namilumab (all doses)
Study: 24794075
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA <1.0 ng/ml
Study: 24794075
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA 1-1.9 ng/ml
Study: 24794075
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA 2-2.9 ng/ml
Study: 24794075
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA 1-1.99 ng/ml
Study: 24794075
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA 2-2.99 ng/ml
Study: 22718472
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT), 10 sessions, 830 nm, output power of 50 mW, fluence of 707 J/cm² (L group, n=23)
Study: 22718472
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (P group, n=20)
Study: 8988795
Drug: dextroamphetamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextroamphetamine (0.25 mg/kg p.o.) + scopolamine (0.5 mg i.v.)
Study: 19211454
Drug: 24 additional
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 additional months of androgen deprivation therapy
Study: 19211454
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional therapy (control arm)
Study: 16394038
Drug: Oxytocin (2.99
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (2.99 IU rapid intravenous infusion)
Study: 16394038
Drug: Oxytocin (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (maximum infusion dose 10.3 +/‐ 8.2 mU/min)
Study: 19780299
Drug: Intraperitoneal (IP)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (IP) chemotherapy regimens
Study: 19780299
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with IP cisplatin
Study: 19780299
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with intravenous cisplatin plus paclitaxel
Study: 11475726
Drug: Radio- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radio- and chemotherapy alone
Study: 780061
Drug: salbutamol 8
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: salbutamol 8 mg tablets (2 tablets b.d.)
Study: 780061
Drug: aminophylline 225
Normalized name: aminophylline 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aminophylline 225 mg tablets (1 tablet b.d. increasing to 2 tablets b.d. after 1 week)
Study: 20112492
Drug: Xiao yan
Normalized name: Xiao mai
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiao yan li dan Pian (bile‐draining anti‐inflammatory tablet)
Study: 8629630
Drug: mupirocin calcium
Normalized name: Mupirocin Calcium
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mupirocin calcium ointment 2% applied daily to the exit site
Study: 8629630
Drug: cyclic oral
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclic oral rifampin 600 mg for 5 days every 3 months
Study: 6691784
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (N = 14)
Study: 6691784
Drug: Pharmacotherapy (N
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (N = 14)